ORIGINAL RESEARCH article
Front. Microbiol.
Sec. Microbial Physiology and Metabolism
Volume 16 - 2025 | doi: 10.3389/fmicb.2025.1669658
Lactobacillus reuteri-derived HDCA suppresses PEDV replication while alleviating virus-triggered inflammation in piglets
Provisionally accepted- 1Institute of Animal Health, Guangdong Academy of Agricultural Sciences, Guangzhou, China
- 2College of Veterinary Medicine, Northwest A&F University, Yangling, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract Background Porcine epidemic diarrhea virus (PEDV) causes severe diarrhea, vomiting, and high mortality in neonatal piglets, but no fully effective treatments or vaccines are currently available. Although gut microbiota transplantation can alleviate post infection symptoms, the specific protective bacterial strains or metabolites involved, along with their underlying mechanisms of action against PEDV, remain unclear. Results Oral administration of L. reuteri GZ-1 or its metabolite hyodeoxycholic acid (HDCA) to three-day-old piglets significantly mitigated clinical symptoms and improved survival outcomes following PEDV challenge. This protection was achieved through five-day pretreatment preceding viral exposure. Both interventions substantially preserved the intestinal architecture, maintaining normal villus height and goblet cell density while markedly reducing PEDV loads in jejunal tissue. Metabolomic profiling established HDCA—a secondary bile acid derivative of L. reuteri metabolism—as the core protective mediator. The direct antiviral activity of HDCA against PEDV was subsequently confirmed through complementary in vitro and in vivo experimental validation. Integrated transcriptomic and proteomic analyses revealed a dual mechanistic pathway underlying HDCA efficacy: (1) suppression of NF-κB-driven inflammatory cascades and (2) activation of interferon-stimulated gene 15 (ISG15)-dependent antiviral pathways. Conclusions This study establishes the L. reuteri-HDCA-TGR5-IFNβ-ISG15 metabolic axis as a novel antiviral pathway. This study identified microbial-derived HDCA as a key effector metabolite that mediates protection against PEDV through the coordinated suppression of inflammation and enhancement of antiviral defenses. These findings highlight microbial-metabolic crosstalk as a promising therapeutic strategy against enteric coronaviruses and provide foundational evidence for commensal-derived interventions to manage porcine epidemic diarrhea.
Keywords: L. reuteri, HDCA, PEDV, Gut Microbiota, piglets
Received: 13 Aug 2025; Accepted: 08 Oct 2025.
Copyright: © 2025 Bian, Gou, Li, Jiang, Chu, Zhai, Kang, Li and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Zhibiao Bian, 97138475@qq.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.